Search results for "surrogate endpoint"

showing 10 items of 71 documents

CA125 but not NT-proBNP predicts the presence of a congestive intrarenal venous flow in patients with acute heart failure

2021

Abstract Background Intrarenal venous flow (IRVF) measured by Doppler ultrasound has gained interest as a potential surrogate marker of renal congestion and adverse outcomes in heart failure. In this work, we aimed to determine if antigen carbohydrate 125 (CA125) and plasma amino-terminal pro-B-type natriuretic peptide (NT-proBNP) are associated with congestive IRVF patterns (i.e., biphasic and monophasic) in acute heart failure (AHF). Methods and results We prospectively enrolled a consecutive cohort of 70 patients hospitalized for AHF. Renal Doppler ultrasound was assessed within the first 24-h of hospital admission. The mean age of the sample was 73.5 ± 12.3 years; 47.1% were female, and…

medicine.medical_specialtymedicine.drug_classCarbohydrates030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineVenous flow03 medical and health sciencesCA1250302 clinical medicineInterquartile rangeIntrarrenal Doppler ultrasoundInternal medicineNatriuretic Peptide BrainmedicineNatriuretic peptideHumans030212 general & internal medicineHeart FailureOriginal Scientific PaperSurrogate endpointbusiness.industryCardiorenalMembrane ProteinsAcute heart failureGeneral Medicinemedicine.diseasePrognosisPeptide FragmentsROC CurveHeart failureCA-125 AntigenCohortNTproBNPCardiologyCongestionFemaleDoppler ultrasoundCardiology and Cardiovascular MedicinebusinessHeart failure with preserved ejection fractionBiomarkers
researchProduct

Clinical outcomes of fractional flow reserve by computed tomographic angiography-guided diagnostic strategies vs. usual care in patients with suspect…

2015

International audience; AIMS: In symptomatic patients with suspected coronary artery disease (CAD), computed tomographic angiography (CTA) improves patient selection for invasive coronary angiography (ICA) compared with functional testing. The impact of measuring fractional flow reserve by CTA (FFRCT) is unknown. METHODS AND RESULTS: At 11 sites, 584 patients with new onset chest pain were prospectively assigned to receive either usual testing (n = 287) or CTA/FFR(CT) (n = 297). Test interpretation and care decisions were made by the clinical care team. The primary endpoint was the percentage of those with planned ICA in whom no significant obstructive CAD (no stenosis \textgreater/=50% by …

MaleCardiac Catheterizationmedicine.medical_specialtymedicine.medical_treatment[SDV]Life Sciences [q-bio]Myocardial InfarctionCoronary Artery DiseaseFractional flow reserveUnnecessary ProceduresCoronary AngiographyChest painCoronary artery diseaseAnginaInternal medicineMyocardial RevascularizationHumansMedicineAngina StableLongitudinal StudiesProspective StudiesMyocardial infarctioncardiovascular diseasesCardiac catheterizationmedicine.diagnostic_testbusiness.industrySurrogate endpointPatient SelectionMiddle Agedmedicine.disease3. Good healthddc:Fractional Flow Reserve MyocardialHospitalizationAngiographyCardiologyFeasibility StudiesFemaleRadiologymedicine.symptomTomography X-Ray ComputedCardiology and Cardiovascular Medicinebusiness
researchProduct

Measurement of exhaled nitric oxide: comparison of 3 different analyzers

2018

Exhaled nitric oxide (FeNO) is used as a surrogate marker to monitor airway inflammation. Aim of this study was to compare the new FeNO analyzer Vivatmo pro from Bosch (BV) with the Niox Vero from Circassia (CN) and the CLD from Ecomedics (EC). In 106 asthma patients (median age 54 years (range 20-87), 60 % female, median ACT of 16, 85 % on inhaled corticosteroids (mean 1300 μg BDP), 36 % on therapy with biologics) 2 FeNO measurements per patient and per device were performed using each analyzer in a random sequence according to the ATS / ERS guidelines. Additionally, the success rate to achieve a valid NO value was evaluated. 70 % of the patients had FeNO values In conclusion, for the rang…

medicine.medical_specialtySurrogate endpointbusiness.industryAirway inflammationInhaled corticosteroidsrespiratory systemmedicine.diseaseGastroenterologyrespiratory tract diseasesInternal medicineExhaled nitric oxidemedicinebusinessAsthmaMonitoring Airway Disease
researchProduct

Physical therapy in heart failure with preserved ejection fraction: A systematic review.

2014

About 50% of patients with heart failure (HF) have preserved ejection fraction (HFpEF) which is especially common in elderly people with highly prevalent co-morbid conditions. HFpEF is usually defined as an ejection fraction equal to or greater than 50%, although some studies have used a limit as low as 40%. The prevalence of this syndrome is expected to increase over the next decades. The associated impact on mortality and hospital readmissions has made of this entity a major public health issue. Despite the fact that mortality and re-hospitalisation rates of HFpEF are similar to the syndrome of HF with reduced ejection fraction (HFrEF), currently there is no available evidence-based thera…

medicine.medical_specialtyEpidemiologyExercise intoleranceComorbidity030204 cardiovascular system & hematologyVentricular Function Left03 medical and health sciences0302 clinical medicineQuality of lifeRisk FactorsInternal medicinemedicinePrevalenceElderly peopleHumans030212 general & internal medicineIntensive care medicinePhysical Therapy ModalitiesHeart FailureEjection fractionExercise ToleranceSurrogate endpointbusiness.industryStroke VolumeRecovery of FunctionExercise capacitymedicine.diseaseTreatment OutcomeHeart failureCardiologyQuality of Lifemedicine.symptomCardiology and Cardiovascular MedicinebusinessHeart failure with preserved ejection fractionEuropean journal of preventive cardiology
researchProduct

The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program o…

2013

BACKGROUND Compliance and persistence are often overlooked in adjuvant breast cancer treatment. PATIENTS AND METHODS PACT was a prospective, multicenter, randomized, open, parallel-group study assessing whether educational materials (EMs) enhanced compliance with aromatase inhibitor (AI) therapy in postmenopausal women with early, hormone-receptor-positive (HR+) breast cancer. The primary end points were compliance (proportion taking ≥ 80% anastrozole) at 12 months and persistence (proportion reporting anastrozole intake during the study period). RESULTS Four thousand eight hundred and forty-four patients were randomly assigned 1:1 to receive standard therapy or standard therapy with EMs. T…

medicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.drug_classmedicine.medical_treatmentAnastrozoleBreast NeoplasmsAnastrozolePactPersistence (computer science)Medication AdherenceEosinophilia–myalgia syndromeBreast cancerInternal medicineNitrilesmedicineHumansProspective StudiesEarly Detection of CancerAgedGynecologyAromatase inhibitorbusiness.industrySurrogate endpointHematologyMiddle AgedTriazolesmedicine.diseasePostmenopauseOncologyPatient ComplianceFemalebusinessAdjuvantmedicine.drugFollow-Up StudiesAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis.

2013

The traditional endpoint for assessing efficacy of chemotherapies for advanced/recurrent gastric cancer is overall survival (OS), but OS requires prolonged follow-up. We investigated whether progression-free survival (PFS) is a valid surrogate for OS. Using individual patient data from the GASTRIC meta-analysis, surrogacy of PFS was assessed through the correlation between the endpoints and through the correlation between the treatment effects on the endpoints. External validation of the prediction based on PFS was also evaluated. Individual data from 4069 patients in 20 randomized trials were analyzed. The rank correlation coefficient between PFS and OS was 0.853 (95% confidence interval […

OncologyCancer Researchmedicine.medical_specialtyBioinformaticsBrief CommunicationDisease-Free Survivallaw.inventionRandomized controlled triallawPredictive Value of TestsStomach NeoplasmsInternal medicinemedicineOdds RatioHumansProgression-free survivalRandomized Controlled Trials as Topicddc:616Surrogate endpointbusiness.industryOdds ratioChemotherapy regimenConfidence intervalTreatment OutcomeOncologyPredictive value of testsMeta-analysisNeoplasm Recurrence LocalbusinessBiomarkersJournal of the National Cancer Institute
researchProduct

A methodological look at the controversy about the influence of salt intake on cardiovascular risk

2012

Cardiovascular diseases are a major cause of premature death and disability. They represent an extraordinarily strong financial burden upon health-care systems in ‘‘developed’’ countries. Elevated blood pressure is a major cause of cardiovascular disease. There is much evidence that cardiovascular risk increases from normal blood pressure (i.e., from 115/75 mmHg upwards) [1]. Overwhelming evidence shows that reducing salt intake from 9–12 g/day to 5–6 g/day lowers blood pressure [2]. Blood pressure is a surrogate endpoint, but may be related to a reduction of morbidity and mortality due to cardiovascular causes. Thus, intensive support and encouragement to cut down on the intake of salt in …

salt intake cardiovascular riskmedicine.medical_specialtyeducation.field_of_studySettore MED/09 - Medicina Internabusiness.industrySurrogate endpointPopulationCochrane LibrarySettore MED/45 - Scienze Infermieristiche Generali Cliniche E Pediatrichelaw.inventionEndocrinologyBlood pressureSystematic reviewRandomized controlled triallawRelative riskInternal medicineEmergency medicineEmergency MedicineInternal MedicinemedicineSalt intakebusinesseducationInternal and Emergency Medicine
researchProduct

Imaging appearance of treated hepatocellular carcinoma

2013

Surgical resection and imaging guided treatments play a crucial role in the management of hepatocellular carcinoma (HCC). Although the primary end point of treatment of HCC is survival, radiological response could be a surrogate end point of survival, and has a key role in HCC decision-making process. However, radiological assessment of HCC treatment efficacy is often controversial. There are few doubts on the evaluation of surgical resection; in fact, all known tumor sites should be removed. However, an unenhancing partial linear peripheral halo, in most cases, surrounding a fluid collection reducing in size during follow-up is demonstrated in successfully resected tumor with bipolar radio…

medicine.medical_specialtyPercutaneousHepatologySurrogate endpointbusiness.industryRadiofrequency ablationmedicine.medical_treatmentHepatocellular carcinoma Imaging TreatmentMinireviewsmedicine.diseaseAblationSurgerylaw.inventionTumor progressionlawHepatocellular carcinomamedicineClinical endpointPercutaneous ethanol injectionbusiness
researchProduct

Inflammation, Endothelial Dysfunction and Arterial Stiffness as Therapeutic Targets in Cardiovascular Medicine

2016

In the last decades, many factors thought to be associated with the atherosclerotic process and cardiovascular events have been studied, and some of these have been shown to correlate with clinical outcome, such as arterial stiffness, endothelial dysfunction and immunoinflammatory markers. Arterial stiffness is an important surrogate marker that describes the capability of an artery to expand and contract in response to pressure changes. It can be assessed with different techniques, such as the evaluation of PWV and AIx. It is related to central systolic pressure and it is an independent predictor of cardiovascular morbidity and mortality in hypertensive patients, type 2 diabetes, end-stage…

medicine.medical_specialtyPathologyEndotheliumPopulation030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineDrug DiscoverymedicineAnimalsHumansPlatelet activationEndothelial dysfunctioneducationInflammationPharmacologyeducation.field_of_studySurrogate endpointbusiness.industryCardiovascular AgentsArteriesmedicine.diseasemedicine.anatomical_structureBlood pressureCardiovascular DiseasesCardiovascular agentArterial stiffnessCardiologyEndothelium Vascularbusiness030217 neurology & neurosurgeryCurrent Pharmaceutical Design
researchProduct

The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer.

2019

Immune checkpoint inhibitors radically changed the treatment of patients with non-small cell lung cancer (NSCLC). However, only one-quarter of patients benefit from these new therapies when used as monotherapy. The assessment of Program Death Ligand-1 (PD-L1) tumor expression by immunohistochemistry is used to select potential responder patients, but this not an optimal marker since it does not predict the absence of anti PD-1 efficacy. Despite this shortcoming, PD-L1 remains the gold standard biomarker in many studies and the only biomarker available for clinicians. In addition to histological markers, transcriptomic and exome analyses have revealed potential biomarkers requiring further c…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentImmune checkpoint inhibitorsReviewlcsh:RC254-282Transcriptome03 medical and health sciences0302 clinical medicineInternal medicinemedicineLung cancerExomebusiness.industrySurrogate endpointbiomarkersImmunotherapymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030104 developmental biologyOncology030220 oncology & carcinogenesisBiomarker (medicine)ImmunohistochemistryimmunotherapyLung cancerbusinessCancers
researchProduct